NeoFipronis Instructions for Use
NeoFipronis (Pronidesivir) GS-441524 represents a groundbreaking advancement in the treatment of Feline Infectious Peritonitis (FIP). Approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, NeoFipronis is the world’s first officially registered, oral therapeutic specifically developed for FIP in cats. Its innovative formulation offers a safe, non-invasive, and highly effective option for managing this often fatal disease.
FIP is caused by a mutated feline coronavirus and manifests through a spectrum of symptoms including inappetence, lethargy, fever, ascites, pleural effusion, lymphadenopathy, granulomatous inflammation, neurological damage, and uveitis. NeoFipronis addresses these clinical signs effectively, with proven rapid absorption, minimal side effects, and excellent tolerability. Its active ingredient, GS-441524, has undergone extensive research and clinical trials, confirming its potent antiviral activity against FIP virus strains.
The medication is administered orally, with dosing based on the cat’s weight. The standard dosage is 15 mg per kilogram of body weight once daily, which equates to half a tablet. For cats exhibiting neurological or ocular forms of FIP, the dose can be increased to 30 mg/kg, but only under veterinarian supervision. It is recommended to give NeoFipronis on an empty stomach—either one hour before feeding or two hours after—to maximize absorption and efficacy.
A crucial aspect of treatment is adherence. NeoFipronis must be given consistently for no less than 12 weeks to ensure complete viral suppression and prevent relapse. Missing doses can compromise treatment outcomes. During therapy, veterinarians and pet owners should monitor the cat’s appetite, activity level, and body temperature regularly. Periodic blood tests, including liver and kidney function assessments, are essential to detect potential adverse effects early.
NeoFipronis is classified as an over-the-counter medication; however, veterinary guidance is strongly advised for optimal results and safety. The medication’s safety profile is high, with minimal reports of side effects. Nonetheless, it is vital to follow dosing instructions carefully and observe the cat closely throughout treatment.
This medication is strictly for feline use. Human consumption or administration can be dangerous. To ensure the authenticity and quality of NeoFipronis, buyers should purchase only from authorized sources listed on the official NeoFipronis website. Ensuring genuine products helps maintain treatment efficacy and safety.
In summary, NeoFipronis (Pronidesivir) GS-441524 offers a highly effective, safe, and convenient oral therapy for cats suffering from FIP. Its rapid action, proven antiviral efficacy, and ease of use have made it a preferred choice among veterinarians and cat owners aiming to improve the quality of life and prognosis of affected felines. Proper adherence to dosage and treatment duration, along with veterinary supervision, can significantly enhance the chance of successful recovery from FIP.
Key Points:
Active Ingredient: GS-441524
Dosing: 15 mg/kg daily; up to 30 mg/kg for neurological/ocular FIP
Administration: Oral, on an empty stomach
Duration: Minimum 12 weeks
Monitoring: Appetite, temperature, blood tests
Safety: High tolerance, minimal side effects
Precautions: Use under veterinary guidance, strictly for cats, purchase from authorized sources
For more information and purchasing options, consult the official NeoFipronis website to ensure product authenticity and quality.
